רווח נקי למניה ב-12 החודשים האחרונים: Tenaya Therapeutics (TNYA)

Risks for Tenaya Therapeutics (TNYA) are linked to R&D costs and patient recruitment rates. The change in profit per unit over the last 12 months on the GURU.Markets chart shows that the parameter value is -0.49. However, patent protection precludes dumping, while Big Pharma's interest in cardio-pipelines and the success of cardiomyopathy treatment trials confirm the uniqueness of the company's technological platform.
Tenaya Therapeutics Inc (TNYA) - פילוחי מדדים ודוחות פיננסיים

Net income per share (TTM) reflects the actual business profitability allocated to a single common share over the last twelve months, excluding the impact of capital structure. By analyzing the change in TTM net income per share, an investor assesses the efficiency of the capital-intensive R&D developments of Tenaya Therapeutics (TNYA), where high patent costs and stringent FDA requirements determine the company's long-term fundamental value.